iRadimed Corporation (NASDAQ:IRMD) reported Q2 2017 earnings this Morning, coming in at $0.06 per share, beating Wall Street’s estimates of ($0.01) per Share. Revenue for the quarter came in at $5.50 million beating analyst estimates of $5.41 million
Analyst Coverage For iRadimed Corporation (NASDAQ:IRMD)
These are 1 Hold Rating .
The current consensus rating for iRadimed Corporation (NASDAQ:IRMD) is Hold (Score: 2.00) with a consensus target price of $11.50 , a potential (17.35% upside)Recent Insider Trading for iRadimed Corporation (NASDAQ:IRMD)
- On 6/1/2017 Steven M Nardi, VP, sold 4,634 with an average share price of $8.32 per share and the total transaction amounting to $38,554.88.
- On 2/9/2017 Roger E Susi, CEO, bought 10,000 with an average share price of $8.60 per share and the total transaction amounting to $86,000.00.
- On 11/29/2016 Roger E Susi, CEO, bought 5,000 with an average share price of $11.24 per share and the total transaction amounting to $56,200.00.
- On 11/15/2016 Roger E Susi, CEO, bought 5,000 with an average share price of $10.46 per share and the total transaction amounting to $52,300.00.
- On 8/16/2016 Steven M Nardi, VP, sold 2,096 with an average share price of $17.11 per share and the total transaction amounting to $35,862.56.
- On 6/14/2016 Monty K. Allen, Director, sold 2,275 with an average share price of $20.00 per share and the total transaction amounting to $45,500.00.
Recent Trading for iRadimed Corporation (NASDAQ:IRMD) Shares of iRadimed Corporation closed the previous trading session at 9.80 up +1.40 16.67% with 89,983 shares trading hands.